https://mirror.vjregenmed.com The Video Journal of Regenerative Medicine Tue, 16 Aug 2022 09:39:54 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.2 https://d2xz56kaqxj8if.cloudfront.net/wp-content/uploads/2023/09/12102509/VJR-Favicon.png https://mirror.vjregenmed.com 32 32 https://mirror.vjregenmed.com/video/0jvttzwf05c-overcoming-issues-associated-with-autologous-therapies/ Tue, 22 Feb 2022 15:00:53 +0000 http://13.40.107.223/video/0jvttzwf05c-overcoming-issues-associated-with-autologous-therapies/ Cate Dyer, CEO & Founder, StemExpress, Folsom, CA, describes strategies to solve problems relating to manufacturing autologous therapies, which are harder to mass produce compared to allogeneic therapies. Collaboration with pharmaceutical companies and hospitals have led to on-site facilities that collect patient cells, which has enabled easier access to allogeneic therapies for patients. She additionally emphasizes the need for collaborators to provide the necessary infrastructure for hospitals to ensure reliable patients cell collection. This interview took place at Advanced Therapies Week 2022.

]]> https://mirror.vjregenmed.com/video/crz4vaph4le-collaborating-with-hospitals-and-industry-in-cell-therapies/ Tue, 22 Feb 2022 15:00:52 +0000 http://13.40.107.223/video/crz4vaph4le-collaborating-with-hospitals-and-industry-in-cell-therapies/ Cate Dyer, CEO & Founder, StemExpress, Folsom, CA, gives an overview of ongoing work by StemExpress in supporting the cell therapy manufacturers in terms of research & development, clinical trials and eventual commercialization. Isolation and collection of cells are a critical part in the production of cell therapies and StemExpress assists in the process, focusing on the logistics of delivering product to and from patients. This interview took place at Advanced Therapies Week 2022.

]]>